New scan could predict lung cancer drug success

NCT ID NCT07151898

Recruiting now Diagnosis Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a special PET scan using a tracer called 68Ga-MY6349 can predict how well a targeted therapy (Trop2-ADC) works in people with advanced non-small cell lung cancer (NSCLC). Fifty adult patients will receive the scan before and during treatment. The goal is to see if changes in the scan can forecast treatment success or failure, potentially guiding future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-MY6349 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a non-invasive way to predict which lung cancer patients will benefit from Trop2-ADC therapy, helping personalize treatment.
What could go wrong: This is an early-stage imaging study with only 50 participants, so results may not apply to all patients. The scan's ability to predict treatment response is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC PET/CT TROP2

Contacts and locations

Locations

The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.